Search SAMHSA Publications and Digital Products
Store Facets Summary
- Clear all filters
- Remove English
- Remove People with Substance Use or Abuse Problems as Population Group
- Remove New Substance Users
- Remove People with Mental Health Problems as Population Group
- Remove Hispanic or Latino
- Remove Racial & Ethnic Groups
- Remove Opioids or Opiates
- Remove Cocaine
- Remove Fentanyl
- Remove Illicit Stimulants
- Remove Inhalants
Main page content
Published: October 2021
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Published: August 2021
The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.
Published: July 2021
This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.
Published: July 2020
This issue brief presents recent data on prevalence of opioid misuse & death rates in the Hispanic/Latino population; contextual factors & challenges to prevention & treatment; innovative outreach & engagement strategies to connect people to evidence-based treatment; and the importance of community voice.